AI Article Synopsis

  • This study explores the potential of monocyte distribution width (MDW) as a biomarker for detecting COVID-19, highlighting the challenges in current testing methods.
  • It involved a retrospective analysis of 80 COVID-19 patients compared to 232 non-COVID-19 patients to evaluate the effectiveness of MDW in distinguishing between the two groups.
  • Findings suggest that an MDW cut-off value of 21.3 could serve as a reliable screening test, with a sensitivity of 81.3% and specificity of 78.2%, particularly in patients presenting with fever.

Article Abstract

Background: Pathogenic genetic testing for coronavirus disease 2019 (COVID-19) can detect viruses with high sensitivity; however, there are several challenges. In the prevention, testing, and treatment of COVID-19, more effective, safer, and convenient methods are desired. We evaluated the possibility of monocyte distribution width (MDW) as an infection biomarker in COVID-19 testing.

Methods: The efficacy of MDW as a screening test for COVID-19 was retrospectively assessed in 80 patients in the COVID-19 group and 232 patients in the non-COVID-19 group (141 patients with acute respiratory infection, 19 patients with nonrespiratory infection, one patient with a viral infection, 11 patients who had received treatment for COVID-19, one patient in contact with COVID-19 patients, and 59 patients with noninfectious disease).

Results: The median MDW in 80 patients in the COVID-19 group was 23.3 (17.2-33.6), and the median MDW in 232 patients in the non-COVID-19 group was 19.0 (13.6-30.2) (P < 0.001). When the COVID-19 group was identified using the MDW cut-off value of 21.3 from the non-COVID-19 group, the area under the curve (AUC) was 0.844, and the sensitivity and specificity were 81.3% and 78.2%, respectively. Comparison of MDW by severity between the COVID-19 group and patients with acute respiratory infection in the non-COVID-19 group showed that MDW was significantly higher in the COVID-19 group for all mild, moderate I, and moderate II disease.

Conclusions: MDW (cut-off value: 21.3) may be used as a screening test for COVID-19 in fever outpatients. Trial registration This study was conducted after being approved by the ethics committee of National Hospital Organization Omuta National Hospital (Approval No. 3-19). This study can be accessed via https://omuta.hosp.go.jp/files/000179721.pdf .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040926PMC
http://dx.doi.org/10.1186/s40001-023-01086-7DOI Listing

Publication Analysis

Top Keywords

covid-19
9
patients
9
monocyte distribution
8
distribution width
8
width mdw
8
mdw screening
8
screening test
8
test covid-19
8
treatment covid-19
8
patients covid-19
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!